CAPAN-2 Xenograft Model Overview

The CAPAN-2 xenograft model is derived from a human pancreatic adenocarcinoma cell line, CAPAN-2, established from a patient with pancreatic ductal adenocarcinoma (PDAC). PDAC is one of the most lethal cancers, known for its late-stage diagnosis, resistance to conventional therapies, and rapid metastasis to distant organs, including the liver, lungs, and peritoneum. The CAPAN-2 xenograft model is widely used in preclinical studies to explore the biology of pancreatic cancer, test novel therapeutic strategies, and investigate mechanisms of drug resistance. Due to its clinical relevance and ability to replicate critical features of human pancreatic cancer, the CAPAN-2 model is valuable for evaluating chemotherapy, targeted therapies, and immunotherapies aimed at improving patient survival.

Request a Custom Quote for CAPAN-2 Xenograft Model

Biological and Molecular Characteristics

CAPAN-2 cells are characterized by their epithelial origin and express typical markers of pancreatic carcinoma, including cytokeratins, epithelial membrane antigen (EMA), and the cancer-associated antigen CA19-9. These cells harbor mutations in the KRAS gene, a hallmark of over 90% of pancreatic cancers, which plays a significant role in tumor initiation, progression, and resistance to treatment. In addition, CAPAN-2 cells exhibit loss of the tumor suppressor gene TP53, which contributes to the rapid proliferation and resistance to apoptosis. The model also shows dysregulated signaling in pathways such as PI3K/AKT and MAPK, both of which are involved in tumor growth, survival, and metastasis. These features make the CAPAN-2 xenograft model particularly useful for studying therapeutic strategies targeting these molecular mechanisms.

Marker	Expression Level	Function
Cytokeratin	High	Epithelial cell marker
EMA	High	Epithelial membrane antigen
CA19-9	Elevated	Pancreatic cancer biomarker
KRAS	Mutated	Oncogene involved in tumor progression
PI3K/AKT pathway	Dysregulated	Promotes cell survival and proliferation

In Vivo Model Development and Tumorigenicity

The CAPAN-2 xenograft model is typically established by implanting CAPAN-2 cells into immunocompromised mice, such as NOD/SCID or NSG mice. Once implanted, the cells form rapidly growing tumors that replicate the clinical features of pancreatic ductal adenocarcinoma, including high cellularity, necrosis, and vascularization. The model is widely used to study tumor growth, metastasis, and the effects of chemotherapy agents, such as gemcitabine and cisplatin, which are commonly used to treat pancreatic cancer. Given its ability to develop resistance to chemotherapy, CAPAN-2 is an excellent model for studying mechanisms of drug resistance and evaluating new therapies aimed at overcoming this resistance.

In addition to subcutaneous implantation, orthotopic implantation of CAPAN-2 cells into the pancreas of immunocompromised mice allows for more clinically relevant studies. This method closely mimics the natural progression of PDAC, enabling the study of primary tumor growth, local invasion, and peritoneal dissemination. The CAPAN-2 orthotopic model is particularly valuable for evaluating therapies targeting the pancreatic tumor microenvironment and metastatic spread.

Request a Custom Quote for CAPAN-2 Xenograft Model

Histopathology and Immunohistochemical Profile

Histopathological analysis of CAPAN-2 xenografts reveals tumors with a characteristic morphology of pancreatic ductal adenocarcinoma, including glandular structures and areas of necrosis. The tumors are composed of pleomorphic cells with abundant cytoplasm and irregular nuclear morphology, indicative of rapid cell division and aggressive tumor behavior. Immunohistochemical staining of CAPAN-2 xenografts shows strong expression of epithelial markers such as cytokeratins and EMA, confirming the epithelial origin of the tumor. Elevated levels of CA19-9 are also detected, a common biomarker in pancreatic cancer patients. Additionally, CAPAN-2 xenografts exhibit activation of the PI3K/AKT pathway, with high levels of phosphorylated AKT, indicating the critical role of this pathway in tumor survival and growth. CD31 staining reveals significant vascularization, highlighting the tumor’s reliance on angiogenesis to support rapid expansion.

Preclinical Applications and Drug Response

The CAPAN-2 xenograft model is widely used in preclinical research to evaluate the efficacy of various chemotherapy agents, including gemcitabine, cisplatin, and 5-fluorouracil. The model’s ability to develop resistance to chemotherapy makes it particularly useful for studying chemotherapy resistance mechanisms and for testing novel agents aimed at overcoming this resistance. CAPAN-2 is also used to evaluate targeted therapies, particularly those that inhibit the KRAS, PI3K/AKT, and MAPK signaling pathways, which are frequently dysregulated in pancreatic cancer.

In addition to chemotherapy and targeted therapies, the CAPAN-2 xenograft model is increasingly used to assess the effectiveness of immunotherapies, including immune checkpoint inhibitors and monoclonal antibodies targeting cancer-specific antigens, such as CA19-9. The model’s ability to replicate key features of PDAC, including its aggressive growth and metastatic potential, makes it an ideal system for studying new therapies that target both the tumor and its microenvironment. Moreover, the CAPAN-2 model is valuable for investigating combination therapies, where chemotherapy is combined with novel inhibitors or immunotherapies to enhance treatment efficacy and prevent resistance.

Request This Model

To request the CAPAN-2 xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for CAPAN-2 Xenograft Model